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Introduction
Charcot-Marie-Tooth (CMT) disease is the most
frequent inherited peripheral neuropathy, with an
estimated prevalence of approximately 1 in 2,500.1
Two major forms of CMT can be identified
electrophysiologically: one shows defects in the
formation or maintenance of myelin (CMT1) and the
other refers to primary axonal degeneration (CMT2).2
A microduplication of 1.5 Mb containing the gene for
peripheral myelin protein 22 (PMP22) on chromosome
17p11.2 is responsible for 75% of cases of the
demyelinating form (CMT1A).3–9  Diagnosis with
markers located inside the duplication is usually carried
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out using restriction fragment length polymorphism
(RFLP) probes3,4,10 and poly(AC) repeats,11,12 less
frequently with fluorescence in situ hybridization
(FISH) analysis,13 rapid real-time fluorescent
polymerase chain reaction (PCR) gene dosage,14 and
multiplex ligation-dependent probe amplification
(MLPA).15 Molecular diagnosis often relies on the
interpretation of differences in allele intensities, even
with the most polymorphic markers that have been
reported to date. When poly(AC) repeats are used for
molecular diagnosis, artifact bands produced by
slippage of the polymerase enzyme may lead to
difficulties in interpretation of dosage for different
alleles. Other useful diagnostic methods have been
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PCR test for CMT1A and HNPP
developed after extensive investigation of the 2 repeated
24-kb sequences (REPs) flanking the duplicated
region.16 A strategy with polymorphic short tandem
repeats (STRs) located inside the CMT1A duplicated
region that allows amplification with very low or no
stuttering, accurate sizing, and visual quantification of
allele intensity was used efficiently.17
Recombination events leading to the CMT1A
duplication occur almost entirely in 4 adjacent regions
within 7.8 kb of the CMT1A-REP sequences, with a
“hot spot” of recombination located in a 3.2-kb
central segment defined by 2 restriction enzyme sites,
EcoRI and SacI.18,19 Characterization of the junction
fragment resulting from recombination allows positive
identification of the duplication with RFLP probes on
Southern blots.18,19
Several methods with direct allele-specific
amplification of the junction fragments by PCR have
also been reported.20–23 However, these methods were
time-consuming and were used with restriction
enzymes to define results. We developed an allele-
specific, all-or-none and rapid PCR method to detect
the junction fragments of CMT1A and hereditary
neuropathy with liability to pressure palsies (HNPP).
Methods
Genomic DNA analysis was performed on 40 unrelated
CMT1A duplication patients, 25 unrelated HNPP
deletion patients, and 50 unaffected control
individuals. The CMT1A and HNPP patients had
previously been identified with microsatellite mapping:
(ATCT)3AT(ATCT)6(ACCT)5 (GenBank accession
no. AC005703), (CAATA)14 (GenBank accession
no. AC0013248), (TTTC)12 (GenBank accession
no. AC0013248), D17S122 (RM11GT), and
D17S921(afm191xh12).17,24 The CMT1A and HNPP
PCR assays described here were carried out in a blind
study. Informed consent was obtained from all subjects
recruited in this study before genetic testing.
Genomic DNA was extracted from peripheral
lymphocytes.25 The following allele-specific primers
were designed according to the published proximal
and distal CMT1A-REP sequences (GeneBank
accession no. U41165-distal and U41166-proximal):
Hot-DF 5' TTGGATTCACAGAGACATTAGTGTTAC-3';
Hot-DR 5'-TAGTAGAGTGAGTACAGTGGAC-3';
Hot-PF 5'-TTGGATTCAAAGATATTAGTGTTAT-3';
Hot-PR 5'-TAGTAGAGCTCACTCTACAG-3'.
The primers Hot-DF and Hot-DR were used for
the normal distal CMT1A-REP, the primers Hot-PF
and Hot-PR were used for the normal proximal
CMT1A-REP, the primers Hot-DF and Hot-PR were
used for the junctional CMT1A repeated fragment,
and Hot-PF and Hot-DR were used for the junctional
HNPP repeated fragment.
Amplification was carried out in 30 +L of 1.5 mM
MgCl2, 50 pmol of each primer, 250 +mol of each
dNTP, 50 ng template DNA, and 2.5 units Taq DNA
polymerase (Takara Bio Inc., Shiga, Japan). The PCR
buffer (10=) was composed of 100 mM Tris-HCl
(pH 8.3), 500 mM KCl, and 15 mM MgCl2.
Amplification was done by initial denaturation at 94$C
for 5 minutes followed by 25 cycles of 30 seconds at
94$C, 1 minute at 56$C, and 3 minutes at 72$C,
including a 1-second autoextension function on the
extension time with a final extension of 5 minutes at
72$C using a PTC-200 Peltier thermal cycler (MJ
Research, Watertown, MA, USA).  Amplified products
were digested with EcoRI and NsiI (New England
Biolabs, Beverly, MA, USA) according to the
manufacturer’s instructions and electrophoresed in
1% agarose gels. Gels were stained in ethidium bromide
(0.1 +g/mL) and visualized under UV light.
Results
The normal distal and proximal CMT1A-REP PCR
assay amplified 3.57- and 3.6-kb segments, respectively,
from 50 normal subjects, 40 CMT1A patients, and
25 HNPP patients using Hot-DF and Hot-DR or
Hot-PF and Hot-PR primers. The CMT1A PCR assay
amplified a 3.58-kb junctional CMT1A-REP fragment
using primers Hot-DF and Hot-PR. However, there
was no PCR product in 50 normal subjects and 25
HNPP patients using this pair of primers. In the
HNPP PCR assay, a 3.6-kb junctional CMT1A-REP
fragment was amplified using primers Hot-PF and
Hot-DR. Furthermore, there was no PCR product
in 50 normal subjects and 40 CMT1A patients
(Figure 1).
Those PCR products of normal distal CMT1A-
REP, normal proximal CMT1A-REP, junctional
CMT1A, and HNPP fragments could be further
digested with EcoRI and NsiI to confirm their effective
amplification. The normal distal CMT1A-REP segment
could be digested by EcoRI, but not NsiI, to generate
3.17- and 0.4-kb fragments. The normal proximal
CMT-REP segment could be digested by NsiI, but
not EcoRI, to generate 2.1- and 1.5-kb fragments.
The junctional CMT1A fragment could be digested
by EcoRI and NsiI to generate 1.7-, 1.5-, and 0.4-kb
fragments. The junctional HNPP fragment could not
be digested by EcoRI or NsiI (Figure 2).
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Figure 1. (A) DF-DR primer set can produce a 3.57-kb PCR product and PF-PR a 3.6 kb product in CMT1A, HNPP and normal controls.
(B) DF-PR primer set can produce a 3.57-kb PCR product only in CMT1A, but not in HNPP and normal controls. (C) PF-DR primer set
can produce a 3.6-kb PCR product only in HNPP, but not in CMT1A and normal controls. bp = base pair; M = base-paired marker.
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Figure 2. Restriction analysis of
EcoRI and NsiI in PCR products
of proximal CMT1A-REP, distal
CMT1A-REP, HNPP, and CMT1A
with agarose gel electrophoresis
and ethidium bromide staining.
There were 2.1 and 1.5 kb in
proximal CMT1A-REP (EcoRI
restriction site), 3.17 and 0.4 kb
(not shown) in distal CMT1A-REP
(NsiI restriction site), 3.6 kb in
HNPP (no restriction sites of
EcoRI and NsiI in recombination
fragments of HNPP) and 1.7, 1.5
and 0.4 kb (not shown) in CMT1A
(EcoRI and NsiI restriction sites).
bp = base pair; M = base-paired
marker; P = proximal; D = distal.
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The CMT1A PCR test detected duplications in 33
of the 40 samples. As expected, the 33 positive results
were obtained from individuals shown by microsatellite
analysis to have crossover breakpoints within the
3.2-kb region, while the remaining 7 lay outside the
3.2-kb region. The HNPP PCR test detected deletions
in 19 of the 25 samples. As expected, the 19 positive
results were obtained from individuals shown by
microsatellite analysis to have a crossover event within
the 3.2-kb region, while the remaining 6 lay outside
the 3.2-kb region. No false positives were detected in
50 unaffected controls tested with both primer sets.
Discussion
Using our method, we have detected 82.5% of CMT1A
and 76% of HNPP patients in this study. Since the
duplication of the PMP-22 gene accounts for 70.7% of
cases of CMT1 and deletion of the PMP22 gene was
present in 84% of the HNPP patients,9,23 screening
for PMP22 gene duplications/deletions obviously
should be the first approach in diagnosing hereditary
demyelinating neuropathy.
Currently available techniques for detecting gene
duplication or deletion are laborious and have specific
drawbacks. Southern blot analysis is a labor-intensive
technique involving the use of radioisotopes,
chemiluminescence, or silver staining. In addition,
partial digestion and/or degradation of the genomic
sample can be problematic. The disadvantage of pulsed
field gel electrophoresis (PFGE) analysis is the need
for sophisticated equipment and fresh cells or blood
samples. Dosage analysis using polymorphic alleles
depends on the informativeness of the marker.
Although PCR-based microsatellite analysis is an
improvement on previously used RFLP probes, the
interpretation of results can be difficult, often requiring
quantitative analysis, and is time-consuming in
comparison with our method. FISH technology is
complex and requires costly apparatus that is not
always available in every DNA diagnostic laboratory.
The development of rapid simple PCR-based tests for
the diagnosis of CMT1A and HNPP would, therefore,
help improve molecular diagnostic services such as
prenatal or postnatal diagnostic tests.23
Haupt et al20 described a PCR-based test using
primers designed to exclusively amplify either the
novel CMT1A or HNPP hybrid fragments. In their
method, however, amplification products were also
obtained from the nonrecombinant CMT1A-REP
regions. Double restriction enzyme digestion of the
PCR products was, therefore, required to distinguish
between normal CMT1A and hybrid CMT1A-specific
repeat (hybrid CMT1A-REP). These assays detected
recombination events within the 1.7-kb hotspot located
between an NsiI site that is unique to the proximal
CMT1A-REP and an EcoRI site that is unique to the
distal CMT1A-REP. The expected detection rate within
this region was 76.9% in CMT1A and 71.9% in HNPP
patients.26 Chang et al27 described a similar test for
CMT1A in which junction-specific primers were used
to amplify the novel 3.2-kb hybrid fragments. No
amplification product was produced in healthy
individuals and in those patients with crossover
breakpoints outside the 3.2-kb region. Although this
produced reliable results, the workload per sample was
still approximately twice that of the CMT1A test we
describe here. Stronach et al22 designed a PCR-based
test that amplified a 3.6-kb region, including the
1.7-kb hotspot from specific CMT1A-REPs. Double
restriction analysis was still required to distinguish
normal and hybrid CMT1A-REPs. Although they
extended the breakpoint region to 3.2 kb and increased
the detection rate to 80% for CMT1A and 95% for
HNPP,22 they could not overcome the problem of
nonspecific amplification.18,22
We used the allele-specific primers Hot-DF and
Hot-PR for the CMT1A test, and Hot-PF and Hot-
DR for the HNPP test, therefore ensuring specific
amplification of the hybrid fragments only. This
overcomes the problem of nonspecific amplification
described by Haupt et al.20
It is important to note that the methods we used
are expected to detect, at most, 82.5% of the patients
with CMT1A duplication and 76% of the patients with
HNPP deletion. A negative result, therefore, does not
exclude the possibility of the diagnosis. In such cases,
multiple unrelated techniques such as microsatellite,17,24
Southern blot,3,28 or MLPA15 have to be employed in
order to confirm or exclude duplication or deletion of
a copy of the PMP22 gene. The negative results may
have resulted from infrequent variation in the CMT1A-
REP sequences,29–31 chimerism of the duplication
junction fragments,32 or possible recombination outside
the CMT1A-REP sequences.33,34 Additionally, as with
any PCR-based technique used in a diagnostic setting,
it is important to include suitable controls against PCR
contamination, as well as positive and negative controls
for the enzymatic digests.
In summary, in this study, stringently specific primers
(Hot-PF, Hot-PR, Hot-DF, and Hot-DR) were used
to overcome the problem of nonspecific amplification
seen in other similar, previously published PCR-based
techniques and provide a rapid, all-or-none and efficient
screening test for CMT1A and HNPP.
K.P. Lin, et al
J Chin Med Assoc • February 2006 • Vol 69 • No 272
Acknowledgment
We gratefully acknowledge a research grant from
National Science Council, Taiwan, R.O.C. (NSC90-
2314-B-075-058).
References
1. Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth’s
disease. Clin Genet 1974;6:98–118.
2. Harding AE, Thomas PK. Genetic aspects of hereditary motor
and sensory neuropathy (types I and II). J Med Genet 1980;17:
329–36.
3. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, Pentao L,
Guzzetta V, Trask BJ, Saucedo-Cardenas O, et al. DNA
duplication associated with Charcot-Marie-Tooth disease type
1A. Cell 1991;66:219–32.
4. Raeymaekers P, Timmerman V, Nelis E, De Jonghe P,
Hoogendijk JE, Baas F, Barker DF, et al. Duplication in
chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy
type 1a (CMT 1a). The HMSN Collaborative Research Group.
Neuromuscul Disord 1991;1:93–7.
5. Patel PI, Roa BB, Welcher AA, Schoener-Scott R, Trask BJ,
Pentao L, Snipes GJ, et al. The gene for the peripheral myelin
protein PMP-22 is a candidate for Charcot-Marie-Tooth disease
type 1A. Nat Genet 1992;1:159–65.
6. Valentijn LJ, Bolhuis PA, Zorn I, Hoogendijk JE, van den
Bosch N, Hensels GW, Stanton VP Jr, et al. The peripheral
myelin gene PMP-22/GAS-3 is duplicated in Charcot-Marie-
Tooth disease type 1A. Nat Genet 1992;1:166–70.
7. Timmerman V, Nelis E, Van Hul W, Nieuwenhuijsen BW,
Chen KL, Wang S, Ben Othman K, et al. The peripheral myelin
protein gene PMP-22 is contained within the Charcot-Marie-
Tooth disease type 1A duplication. Nat Genet 1992;1:171–5.
8. Matsunami N, Smith B, Ballard L, Lensch MW, Robertson M,
Albertsen H, Hanemann CO, et al. Peripheral myelin protein-
22 gene maps in the duplication in chromosome 17p11.2
associated with Charcot-Marie-Tooth 1A. Nat Genet 1992;1:
176–9.
9. Nelis E, Van Broeckhoven C, De Jonghe P, Lofgren A,
Vandenberghe A, Latour P, Le Guern E, et al. Estimation of
the mutation frequencies in Charcot-Marie-Tooth disease type
1 and hereditary neuropathy with liability to pressure palsies: a
European collaborative study. Eur J Hum Genet 1996;4:
25–33.
10. Hensels GW, Janssen EA , Hoogendijk JE, Valentijn LJ, Baas
F, Bolhuis PA. Quantitative measurement of duplicated DNA
as a diagnostic test for Charcot-Marie-Tooth disease type 1a.
Clin Chem 1993;39:1845–9.
11. Cudrey C, Chevillard C, Le Paslier D, Vignal A, Passage E,
Fontes M. Assignment of microsatellite sequences to the
region duplicated in CMT1A (17p12): a useful tool for
diagnosis. J Med Genet 1995;32:231–3.
12. Blair IP, Kennerson ML, Nicholson GA. Detection of Charcot-
Marie-Tooth type 1A duplication by the polymerase chain
reaction. Clin Chem 1995;41:1105–8.
13. Rautenstrauss B, Fuchs C, Liehr T, Grehl H, Murakami T,
Lupski JR. Visualization of the CMT1A duplication and HNPP
deletion by FISH on stretched chromosome fibers. J Peripher
Nerv Syst 1997;2:319–22.
14. Ruiz-Ponte C, Loidi L, Vega A, Carracedo A, Barros F. Rapid
real-time fluorescent PCR gene dosage test for the diagnosis of
DNA duplications and deletions. Clin Chem 2000;46:1574–82.
15. Slater H, Bruno D, Ren H, La P, Burges T, Hills L, Nouri S,
et al. Improved testing for CMT1A and HNPP using multiplex
ligation-dependent probe amplification (MLPA) with rapid
DNA preparations: comparison with the interphase FISH
method. Hum Mutat 2004;24:164–71.
16. Pentao L, Wise CA, Chinault AC, Patel PI, Lupski JR. Charcot-
Marie-Tooth type 1A duplication appears to arise from
recombination at repeat sequences flanking the 1.5 Mb
monomer unit. Nat Genet 1992;2:292–300.
17. Latour P, Boutrand L, Levy N, Bernard R, Boyer A, Claustrat
F, Chazot G, et al. Polymorphic short tandem repeats for
diagnosis of the Charcot-Marie-Tooth 1A duplication. Clin
Chem 2001;47:829–37.
18. Reiter LT, Murakami T, Koeuth T, Pentao L, Muzny DM,
Gibbs RA, Lupski JR. A recombination hotspot responsible for
two inherited peripheral neuropathies is located near a mariner
transposon-like element. Nat Genet 1996;12:288–97.
19. Lopes J, LeGuern E, Gouider R, Tardieu S, Abbas N, Birouk
N, Gugenheim M, et al. Recombination hot spot in a 3.2-kb
region of the Charcot-Marie-Tooth type 1A repeat sequences:
new tools for molecular diagnosis of hereditary neuropathy
with liability to pressure palsies and of Charcot-Marie-Tooth
type 1A. French CMT Collaborative Research Group. Am J
Hum Genet 1996;58:1223–30.
20. Haupt A, Schols L, Przuntek H, Epplen JT. Polymorphisms in
the PMP-22 gene region (17p11.2-12) are crucial for simplified
diagnosis of duplications/deletions. Hum Genet 1997;99:
688–91.
21. Yamamoto M, Keller MP, Yasuda T, Hayasaka K, Ohnishi A,
Yoshikawa H, Yanagihara T, et al. Clustering of CMT1A
duplication breakpoints in a 700 bp interval of the CMT1A-
REP repeat. Hum Mutat 1998;11:109–13.
22. Stronach EA, Clark C, Bell C, Lofgren A, McKay NG,
Timmerman V, Van Broeckhoven C, et al. Novel PCR-based
diagnostic tools for Charcot-Marie-Tooth type 1A and
hereditary neuropathy with liability to pressure palsies. J Peripher
Nerv Syst 1999;4:117–22.
23. Bernard R, Labelle V, Negre P, Tardieu S, Azulay JP, Malzac
P, Mattei JF, et al. Prenatal detection of a 17p11.2 duplication
resulting from a rare recombination event and novel PCR-
based strategy for molecular identification of Charcot-Marie-
Tooth disease type 1A. Eur J Hum Genet 2000;8:229–35.
24. LeGuern E, Ravise N, Gouider R, Gugenheim M, Lopes J,
Bouche P, Agid Y, et al. Microsatellite mapping of the deletion
in patients with hereditary neuropathy with liability to pressure
palsies (HNPP): new molecular tools for the study of the
region 17p12 A p11 and for diagnosis. Cytogenet Cell Genet
1996;72:20–5.
25. Sambrook JFE, Maniatis T. Molecular Cloning, 2nd edition.
New York: Cold Spring Harbor Laboratory Press, 1989.
26. Timmerman V, Rautenstrauss B, Reiter LT, Koeuth T, Lofgren
A, Liehr T, Nelis E, et al. Detection of the CMT1A/HNPP
recombination hotspot in unrelated patients of European
descent. J Med Genet 1997;34:43–9.
27. Chang JG, Jong YJ, Wang WP, Wang JC, Hu CJ, Lo MC,
Chang CP. Rapid detection of a recombinant hotspot associated
with Charcot-Marie-Tooth disease type IA duplication by a
PCR-based DNA test. Clin Chem 1998;44:270–4.
28. Lupski JR. DNA diagnostics for Charcot-Marie-Tooth disease
and related inherited neuropathies. Clin Chem 1996;42:
995–8.
29. Reiter LT, Hastings PJ, Nelis E, De Jonghe P, Van Broeckhoven
C, Lupski JR. Human meiotic recombination products revealed
by sequencing a hotspot for homologous strand exchange in
multiple HNPP deletion patients. Am J Hum Genet 1998;62:
1023–33.
PCR test for CMT1A and HNPP
J Chin Med Assoc • February 2006 • Vol 69 • No 2 73
30. Lopes J, Ravise N, Vandenberghe A, Palau F, Ionasescu V,
Mayer M, Levy N, et al. Fine mapping of de novo CMT1A and
HNPP rearrangements within CMT1A-REPs evidences two
distinct sex-dependent mechanisms and candidate sequences
involved in recombination. Hum Mol Genet 1998;7:141–8.
31. Fuchs C, Liehr T, Ozbey S, Ekici A, Grehl H, Rautenstrauss B.
Charcot-Marie-Tooth disease type 1A and hereditary
neuropathy with liability to pressure palsies: a SacI polymorphism
in the proximal CMT1A-REP elements may lead to genetic
misdiagnosis. Neurogenetics 1998;2:43–6.
32. Lopes J, Tardieu S, Silander K, Blair I, Vandenberghe A, Palau
F, Ruberg M, et al. Homologous DNA exchanges in humans
can be explained by the yeast double-strand break repair
model: a study of 17p11.2 rearrangements associated with
CMT1A and HNPP. Hum Mol Genet 1999;8:2285–92.
33. Valentijn LJ, Baas F, Zorn I, Hensels GW, de Visser M, Bolhuis
PA. Alternatively sized duplication in Charcot-Marie-Tooth
disease type 1A. Hum Mol Genet 1993;2:2143–6.
34. Vandenberghe A, Latour P, Chauplannaz G, Chapon F, Pouget
J, Dumas R, Laguenay A, et al. Molecular diagnosis of Charcot-
Marie-Tooth 1A disease and hereditary neuropathy with liability
to pressure palsies by quantifying CMT1A-REP sequences:
consequences of recombinations at variant sites on chromosomes
17p11.2-12. Clin Chem 1996;42:1021–5.
